SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Strategies & Market Trends : The Canine Corner(Shorters Paradise) -- Ignore unavailable to you. Want to Upgrade?


To: DJRoss who wrote (29)8/7/1998 6:14:00 AM
From: Q.  Read Replies (1) | Respond to of 45
 
Nice thread, guys.

I like the idea of screening Schonberg's holdings for short ideas, but ulgx has apparently fallen about as far as it can already: The stock is at $6, and they have $3 1/2 per share of cash.

re. urinating on fire hydrants, that's somehow appropriate, Dug. The co. sells urological products.



To: DJRoss who wrote (29)8/10/1998 8:16:00 AM
From: RockyBalboa  Respond to of 45
 
Zonagen Update

Zonagen reports a loss of 6c a share for 2q 98. Revenues up mostly of the $5 M milestone fee from Schering, which came in accelerated, and a bit of royalties. Loss results from the devel. expenses up, attributed to the devel. of Vasomax.
Firm states still $60M cash.
Shares out, average >11 Mio.

I think I will put it on the watchlist as co doesn't burn that much money and seems to be able to generate some revenues. It may rise to $20 again after this and soon-to-be made annoucements to promote Vasomax.

Though, numbers are unaudited. And, stemming from the last annual reports (31.3.1998), Zonagen is notorious in activating money from exercising options granted to directeurs and staff, recognizing portions of it pro rata. Who knows whether all of the options will ever be exercised esp. those with a $30 Strike. Still, the market risk resulting from this recognition of income is not stated in the 10A. Well, numbers are peanuts.

sec.yahoo.com

Christian